Rebamipide + nizatidine is effective and safe to treat erosive gastritis, with superior mucosal erosion improvement and comparable symptom relief when compared to nizatidine alone.
In a phase 4 study issued in "World Journal of Gastroenterology", combining rebamipide 150 mg (mucoprotective agent) with nizatidine 150 mg (gastric acid suppressant) improved mucosal erosions more successfully than nizatidine alone in erosive gastritis patients. With the goal of comparing the efficacy and safety of rebamipide + nizatidine vs. nizatidine alone, this randomized trial enrolled 260 patients suffering from endoscopically confirmed erosive gastritis.
Participants received either rebamipide/nizatidine or nizatidine alone twice daily for 2 weeks. The full-analysis set included 239 patients, and the per-protocol analysis covered 218 patients. Researchers assessed erosion improvement, symptom relief, and safety outcomes. The combination therapy showed a remarkably higher erosion improvement rate in the full-analysis set. Similar trends appeared in the per-protocol analysis (Table 1).
Both groups depicted improvements in erosion, edema, erythema, bleeding, and gastrointestinal symptoms, with no significant inter-group differences. In those experiencing gastritis symptoms, the combination group exhibited a more pronounced erosion improvement (63.0% vs. 49.5%). No drug-related adverse events were reported. Hence, rebamipide/nizatidine combination therapy may offer a superior treatment option for erosive gastritis by enhancing mucosal healing while controlling symptoms.
World Journal of Gastroenterology
Efficacy and safety of rebamipide/nizatidine in patients with erosive gastritis: A randomized, multicenter, phase 4 study
Donghoon Kang et al.
Comments (0)